Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 4/2010

Ausgabe 4/2010

Inhaltsverzeichnis ( 19 Artikel )

01.08.2010 | PRECLINICAL STUDIES | Ausgabe 4/2010

Evaluation Of 5-hydroxy-2,3-diaryl (substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anti angiogenic and anticancer agents

Vinod Kumar Sanna, Manu Jaggi, Vadlapudi Kumar, Anand C. Burman

01.08.2010 | PRECLINICAL STUDIES | Ausgabe 4/2010

Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity

Satoki Nakamura, Mitsuji Yamashita, Daisuke Yokota, Isao Hirano, Takaaki Ono, Michio Fujie, Kiyoshi Shibata, Taishi Niimi, Takuya Suyama, Kasthuraiah Maddali, Kazuhide Asai, Junko Yamashita, Yukiko Iguchi, Kazunori Ohnishi

01.08.2010 | PRECLINICAL STUDIES | Ausgabe 4/2010

The neem limonoids azadirachtin and nimbolide inhibit cell proliferation and induce apoptosis in an animal model of oral oncogenesis

G. Harish Kumar, R. Vidya Priyadarsini, G. Vinothini, P. Vidjaya Letchoumy, S. Nagini

01.08.2010 | PRECLINICAL STUDIES | Ausgabe 4/2010

MER1, a novel organic arsenic derivative, has potent PML-RARα- independent cytotoxic activity against leukemia cells

Mirna Golemovic, Alfonso Quintás-Cardama, Taghi Manshouri, Nada Orsolic, Hatice Duzkale, Mary Johansen, Emil J. Freireich, Hagop Kantarjian, Ralph A. Zingaro, Srdan Verstovsek

01.08.2010 | PRECLINICAL STUDIES | Ausgabe 4/2010

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines

Brigette B. Y. Ma, Vivian W. Y. Lui, Edwin P. Hui, Cecilia P. Y. Lau, Kakiu Ho, Margaret H. L. Ng, S. H. Cheng, Sai-Wah Tsao, Anthony T. C. Chan

01.08.2010 | PRECLINICAL STUDIES | Ausgabe 4/2010

Cytotoxic activities of new iron(III) and nickel(II) chelates of some S-methyl-thiosemicarbazones on K562 and ECV304 cells

Belkıs Atasever, Bahri Ülküseven, Tülay Bal-Demirci, Serap Erdem-Kuruca, Zeynep Solakoğlu

01.08.2010 | PRECLINICAL STUDIES | Ausgabe 4/2010

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines

D. M. Collins, J. Crown, N. O’Donovan, A. Devery, F. O’Sullivan, L. O’Driscoll, M. Clynes, R. O’Connor

01.08.2010 | PRECLINICAL STUDIES | Ausgabe 4/2010

The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12

Eva Roubalová, Veronika Kvardová, Roman Hrstka, Šárka Bořilová, Eva Michalová, Lenka Dubská, Petr Müller, Petr Sova, Bořivoj Vojtěšek

01.08.2010 | PRECLINICAL STUDIES | Ausgabe 4/2010

Synthesis and identification of a new class of (S)-2,6-diamino-4,5,6,7-tetrahydrobenzo[d]thiazole derivatives as potent antileukemic agents

D. S. Prasanna, C. V. Kavitha, B. Raghava, K. Vinaya, S. R. Ranganatha, Sathees C. Raghavan, K. S. Rangappa

01.08.2010 | PRECLINICAL STUDIES | Ausgabe 4/2010

Tea polyphenols inhibit cyclooxygenase-2 expression and block activation of nuclear factor-kappa B and Akt in diethylnitrosoamine induced lung tumors in Swiss mice

Preeti Roy, Nidhi Nigam, Madhulika Singh, Jasmine George, Smita Srivastava, Hasnain Naqvi, Yogeshwer Shukla

01.08.2010 | PRECLINICAL STUDIES | Ausgabe 4/2010

Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents

Xishan Xiong, Li Wang, Yangliang Ye, Lili Fu, Minli Chen, Qingyi Wang, Moyan Liu, Jing Tang, Bing Dai, Jianhua Shen, Changlin Mei

01.08.2010 | PRECLINICAL STUDIES | Ausgabe 4/2010

Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil

Milica Pešić, Ana Podolski, Ljubiša Rakić, Sabera Ruždijić

01.08.2010 | PRECLINICAl STUDIES | Ausgabe 4/2010

Novel combretastatin A-4 derivative XN0502 induces cell cycle arrest and apoptosis in A549 cells

Hong Zhu, Jun Zhang, Na Xue, Yongzhou Hu, Bo Yang, Qiaojun He

01.08.2010 | PHASE I STUDIES | Ausgabe 4/2010

Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC Regimen)in advanced malignancies

Robert Wesolowski, David Peereboom, Patricia Weiss, Paul Elson, George Thomas Budd

01.08.2010 | PHASE I STUDIES | Ausgabe 4/2010

A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors

Anne M. Traynor, Michael S. Gordon, Dona Alberti, David S. Mendelson, Mark S. Munsey, George Wilding, Richard E. Gammans, William L. Read

01.08.2010 | PHASE II STUDIES | Ausgabe 4/2010

Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Byung Woog Kang, Won Seog Kim, Chul Kim, Geundoo Jang, Sung Sook Lee, Yoon Hee Choi, Dae Ho Lee, Sang We Kim, Shin Kim, Jin-Sook Ryu, Jooryung Huh, Jung Shin Lee, Cheolwon Suh

01.08.2010 | PHASE II STUDIES | Ausgabe 4/2010

Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors

Darren R. Feldman, Stefan Turkula, Michelle S. Ginsberg, Nicole Ishill, Sujata Patil, Maryann Carousso, George J. Bosl, Robert J. Motzer

01.08.2010 | SHORT REPORT | Ausgabe 4/2010

Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients

Antoine Hollebecque, Antoine Adenis, Sophie Taieb, Claudia Lebedinsky, Nicolas Penel

01.08.2010 | SHORT REPORT | Ausgabe 4/2010

Reversible cardiogenic shock following 5-Fluorouracil infusion

Charles Ferté, Carlos Gomez Roca, Yohann Loriot, Rastislav Bahleda, Cristian Moldovan, Ariel Cohen, Hassan Izzedine, Jean-Charles Soria, Stephane Ederhy

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise